Tickers

1. Composite Trajectory Verdict

For a medical technology company with recurring revenue streams and high operating leverage, the income statement trajectory matters most as it reflects progress toward profitability, though cash generation and balance sheet durability are equally critical for sustaining operations given ongoing losses.

Composite Trajectory: Mixed

The annual income statement shows consistent improvement across three years: revenue grew 2.9% to $822.3 million (10-K 2025-12-31, Consolidated Statements of Operations), gross margin expanded to 68.8% from 65.1% (10-K 2025-12-31, MD&A), and net loss narrowed to -$92.2 million from -$151.4 million (10-K 2025-12-31, Consolidated Statements of Operations). However, the cash flow statement diverges: annual operating cash flow improved to $33.3 million in FY2025 from -$45.8 million in FY2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows), yet year-to-date 2026 operating cash flow deteriorated to -$23.8 million versus -$6.8 million in the prior year period (10-Q 2026-06-30, Consolidated Statements of Cash Flows). The balance sheet shows rising leverage (long-term debt increased to $221.6 million at June 30, 2026 from $157.4 million at December 31, 2025 per 10-Q 2026-06-30 and 10-K 2025-12-31 balance sheets) and declining equity ($429.2 million at June 30, 2026 versus $503.1 million at December 31, 2024 per same sources), driven by accumulated deficit growth.

2. Red Flags

• Operating cash flow reversal in 2026: YTD June 2026 operating cash flow was -$23.8 million versus -$6.8 million YTD June 2025 (10-Q 2026-06-30, Consolidated Statements of Cash Flows), despite improved operating losses, driven by a $20.9 million inventory build (10-Q 2026-06-30, Consolidated Statements of Cash Flows) versus a $5.9 million decrease in the prior year period.
• Debt increase without proportional cash generation: Long-term debt rose $64.2 million in Q1 2026 (Term B Loan draw per 10-K 2025-12-31, MD&A; 10-Q 2026-03-31, Consolidated Statements of Cash Flows shows $64.0 million proceeds) while YTD 2026 free cash flow was -$47.0 million (operating -$23.8M + investing -$23.2M per 10-Q 2026-06-30).
• Accumulated deficit accelerating: Accumulated deficit grew to -$405.0 million at June 30, 2026 from -$368.3 million at December 31, 2025 and -$276.1 million at December 31, 2024 (10-Q 2026-06-30, 10-K 2025-12-31, Consolidated Balance Sheets), eroding equity to $429.2 million from $503.1 million over 18 months.
• Acquisition-related amortization/impairment rising: Annual expense increased to $27.3 million in FY2025 from $14.8 million in FY2023 (10-K 2025-12-31, Consolidated Statements of Operations), including $11.0 million impairment from M6 discontinuation (10-K 2025-12-31, MD&A).
• Legal/contingent liabilities recurring: $17.6 million SG&A increase in FY2025 from "certain legal matters, including ongoing arbitration" (10-K 2025-12-31, MD&A); Lattus contingent consideration fair value $7.9 million at December 31, 2025 with $6.3 million paid in 2025 (10-K 2025-12-31, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Annual results show three consecutive years of revenue growth (FY2023 $746.6M → FY2024 $799.5M → FY2025 $822.3M per 10-K 2025-12-31, Consolidated Statements of Operations) and gross margin expansion (65.1% → 68.3% → 68.8% per 10-K 2025-12-31, MD&A). Operating loss narrowed from -$139.1 million in FY2023 to -$81.4 million in FY2025, and net loss from -$151.4 million to -$92.2 million (10-K 2025-12-31, Consolidated Statements of Operations). R&D expense declined as a percentage of sales from 10.7% to 8.0% over the same period (10-K 2025-12-31, MD&A). Quarterly YoY comparison is mixed: Q1 2026 operating loss improved to -$14.4 million from -$48.9 million in Q1 2025, but Q2 2026 net loss widened slightly to -$15.8 million from -$14.1 million in Q2 2025 despite a smaller operating loss (-$8.1M vs -$16.0M per 10-Q 2026-06-30, Consolidated Statements of Operations), due to higher net interest expense and other expense.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow improved markedly from -$45.8 million in FY2023 to $25.8 million in FY2024 and $33.3 million in FY2025 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow remained negative but narrowed from -$9.1 million in FY2024 to -$1.3 million in FY2025 (10-K 2025-12-31, MD&A). However, the first half of 2026 reversed this trend: YTD June 2026 operating cash flow was -$23.8 million versus -$6.8 million in the prior year period (10-Q 2026-06-30, Consolidated Statements of Cash Flows), driven by a $20.9 million inventory increase versus a $5.9 million decrease previously (same source). Investing cash outflows doubled to -$23.2 million YTD June 2026 from -$13.8 million (10-Q 2026-06-30 vs 10-Q 2025-06-30, Consolidated Statements of Cash Flows). Financing inflows of $66.4 million YTD June 2026 (primarily the Term B Loan draw) offset operating and investing uses, resulting in a net cash increase of $19.3 million (10-Q 2026-06-30, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets declined from $893.3 million at December 31, 2024 to $850.6 million at December 31, 2025 (10-K 2025-12-31, Consolidated Balance Sheets), then rose to $873.0 million at June 30, 2026 (10-Q 2026-06-30, Consolidated Balance Sheets) primarily from debt-funded cash. Long-term debt increased from $157.0 million at December 31, 2024 to $157.4 million at December 31, 2025 (10-K 2025-12-31, Consolidated Balance Sheets) and jumped to $221.6 million at June 30, 2026 after the $65.0 million Term B Loan draw (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, MD&A). Shareholders' equity fell from $503.1 million to $450.0 million to $429.2 million over the same three points (same sources), driven by accumulated deficit growth to -$405.0 million. Inventory rose from $172.3 million to $184.5 million between December 31, 2025 and June 30, 2026 (10-K 2025-12-31 and 10-Q 2026-06-30, Consolidated Balance Sheets), while days sales in receivables remained at 57 days (10-K 2025-12-31, MD&A). The company remained in compliance with credit facility covenants as of December 31, 2025 (10-K 2025-12-31, MD&A).

6. Data Gaps

• FY2023 full balance sheet (only partial data in 10-K 2025-12-31 XBRL) – would require 10-K for FY2023
• Q3 and Q4 2025 quarterly statements (only annual FY2025 and Q1-Q2 2026 provided) – would require 10-Qs for 2025-09-30 and 2025-12-31 (latter is 10-K)
• Q3 2026 results (not yet filed) – would require 10-Q for 2026-09-30
• Segment-level operating profit/loss (not disclosed in filings provided) – would require segment reporting footnote with profitability
• Adjusted EBITDA reconciliation to GAAP (referenced but not quantified in provided excerpts) – would require full MD&A or earnings release
• Debt maturity schedule beyond "monthly amortization January 2029–November 2029" (10-K 2025-12-31, MD&A) – would require debt footnote with full schedule
• Inventory turn and DSO for quarterly 2026 periods (only annual FY2024/FY2025 provided in MD&A) – would require quarterly MD&A disclosure